Trial
NCT03243760
Dose Escalating Study of CCI15106 Inhalation Capsules in Healthy Subjects and Moderate Chronic Obstructive Pulmonary Disease (COPD) Patients
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Pulmonary Disease, Chronic Obstructive
Intervention
CCI15106 7.5 mg capsule
Why stopped
The trial is terminated before investigation of repeat escalating doses as these will be conducted with the new formulation instead.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-06-30